Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel oral agents for multiple sclerosis.

Jodie M Burton1, Paul O'Connor

  • 1Multiple Sclerosis Clinic, Division of Neurology, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada. burtonj@smh.toronto.on.ca

Current Neurology and Neuroscience Reports
|May 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medicine and motherhood: a cross-sectional survey of the experiences of women doctors in the Republic of Ireland.

BMC women's health·2026
Same author

Health and safety considerations for healthcare simulation: a scoping review of published literature.

Advances in simulation (London, England)·2026
Same author

Addressing under-appreciated risk in healthcare simulation.

Advances in simulation (London, England)·2026
Same author

Building excellence in simulation programs: Experiences and examples from ASPIRE Award recipients and panellists.

Medical teacher·2026
Same author

Measuring Situation Awareness: A Meta-Review Across Domains.

Human factors·2026
Same author

Use of Health Care Simulation in Air Medical Settings: A Scoping Review.

Air medical journal·2026
Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026
Same journal

Astrocytopathy in Wernicke Encephalopathy and Neuromyelitis Optica Spectrum Disorder. Pathogenic Differences With Occasional Clinical and Neuroimaging Overlap. A Review.

Current neurology and neuroscience reports·2026
Same journal

When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?

Current neurology and neuroscience reports·2026
Same journal

Assessment and Management of Post-traumatic Headache.

Current neurology and neuroscience reports·2026
See all related articles

New oral medications show promise for multiple sclerosis (MS) treatment, offering an alternative to injectable therapies. These agents are being evaluated in clinical trials for efficacy and tolerability.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Interferon beta-1b, approved in 1993, was the first disease-modifying therapy for multiple sclerosis (MS).
  • Current MS treatments, primarily injectable interferons, effectively reduce relapses and MRI lesions but face challenges with patient adherence due to administration route.
  • Decades of research into oral MS therapies have yielded mixed results, necessitating novel approaches.

Purpose of the Study:

  • To review the efficacy and tolerability of promising oral agents for multiple sclerosis currently in late-stage clinical trials.
  • To assess the potential of new oral medications as alternatives to parenteral disease-modifying therapies for MS.

Main Methods:

  • Review of scientific literature and clinical trial data for oral multiple sclerosis agents.
  • Assessment of efficacy, safety, and tolerability profiles of selected oral medications in phase II/III trials.

Related Experiment Videos

Main Results:

  • Several oral agents in development demonstrate significant promise in clinical trials.
  • These emerging oral therapies are being evaluated for their potential to improve patient adherence and treatment outcomes in MS.

Conclusions:

  • Oral therapies represent a significant advancement in multiple sclerosis management.
  • Upcoming approvals of novel oral agents may offer more convenient and effective treatment options for patients with MS.